Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy

被引:42
|
作者
George, L
Bladou, F
Bardou, VJ
Gravis, G
Tallet, A
Alzieu, C
Serment, G
Salem, N
机构
[1] Hop Salvator, Dept Urol, F-13274 Marseille 9, France
[2] Inst J Paoli I Calmettes, Dept Radiotherapy, F-13009 Marseille, France
[3] Inst J Paoli I Calmettes, Dept Med Oncol, F-13009 Marseille, France
[4] Inst J Paoli I Calmettes, Dept Biostat, F-13009 Marseille, France
关键词
D O I
10.1016/j.urology.2004.04.088
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objectives. To describe the outcome of patients with muscle-invasive bladder carcinoma treated with multimodality therapy in our institution from 1993 to 2002. Methods. The charts of 60 patients with Stage T2-T4N0-N1M0 treated with transurethral resection of bladder tumor followed by a chemoradiotherapy combination were retrospectively reviewed. Of the 60 patients, 22 had received neoadjuvant chemotherapy (methotrexate, cisplatin, and vinblastine or methotrexate, adriamycin, cisplatin, and vinblastine) followed by concomitant chemoradiotherapy (weekly cisplatin/carboplatin or a cisplatin and 5-fluorouracil combination), and 38 had received concomitant chemoradiotherapy alone. Radiotherapy delivered a median dose of 45 Gy to the pelvis and 65 Gy to the bladder in a once-daily or twice-daily fractionation scheme. Follow-up evaluations included cystoscopy with biopsies at regular intervals. Salvage cystectomy was recommended in the case of local persistent tumor or bladder relapse. Results. The median follow-up was 48.5 months (range 10 to 126). Of the 22 patients who received neoadjuvant chemotherapy, 18 (82%) had received two or more cycles; 51 (85%) of the 60 patients received the concomitant chemotherapy as planned. Radiotherapy was completed in 56 patients. Twenty-eight patients developed relapse either locally (14 did not achieve a complete local response after chemoradiotherapy and 6 had true local relapse during follow-up) or at distant sites. The actuarial 5-year disease-specific survival and freedom from local and distant relapse rate was 54% and 42%, respectively. The actuarial local control rate with an intact bladder was 56% at 5 years. When stratified according to stage and grade, patients with Stage T2-T3, grade 2 tumors had a statistically significantly better chance of remaining relapse free than did the others (P = 0.045). Salvage cystectomy (n = 11) for isolated local failure in this population achieved limited results. Conclusions. Transurethral resection of bladder tumor with this chemoradiotherapy combination achieved satisfactory results in this unfavorable Population with invasive bladder carcinoma.
引用
收藏
页码:488 / 493
页数:6
相关论文
共 50 条
  • [31] Clinical outcome of conservative therapy for stage T1, grade 3 transitional cell carcinoma of the bladder
    Hara, I
    Miyake, H
    Takechi, Y
    Eto, H
    Gotoh, A
    Fujisawa, M
    Okada, H
    Arakawa, S
    Kamidono, S
    [J]. INTERNATIONAL JOURNAL OF UROLOGY, 2003, 10 (01) : 19 - 24
  • [32] Long term outcome of patients with locally advanced thyroid carcinoma
    Powles, J
    Vini, L
    Hern, RA
    Harmer, C
    Rhys-Evans, P
    [J]. BRITISH JOURNAL OF CANCER, 2000, 83 : 50 - 50
  • [33] Clinical outcome of recurrent locally advanced cervical cancer (LACC) submitted to primary multimodality therapies
    Legge, F.
    Chiantera, V.
    Macchia, G.
    Fagotti, A.
    Fanfani, F.
    Ercoli, A.
    Gallotta, V.
    Morganti, A. G.
    Valentini, V.
    Scambia, G.
    Ferrandina, G.
    [J]. GYNECOLOGIC ONCOLOGY, 2015, 138 (01) : 83 - 88
  • [34] Clinical outcome and cosmesis in African-American patients treated with conservative surgery and radiation therapy
    Tuamokumo, NL
    Haffty, BG
    [J]. CANCER JOURNAL, 2003, 9 (04): : 313 - 320
  • [35] Multimodality Local Therapy Improves Survival Without Hastening Liver Failure in Patients With Locally Advanced Hepatocellular Carcinoma.
    Renz, P.
    Hasan, S.
    Abel, S.
    Uemura, T.
    Machado, L.
    Thai, N.
    Kirichenko, A. V.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 99 (02): : E181 - E181
  • [36] Race and clinical outcome in patients with carcinoma of the uterine cervix treated with radiation therapy
    Mundt, AJ
    Connell, PP
    Campbell, T
    Hwang, JH
    Rotmensch, J
    Waggoner, S
    [J]. GYNECOLOGIC ONCOLOGY, 1998, 71 (02) : 151 - 158
  • [37] A prospective study of conservative multimodality treatment for locally advanced head/neck cancer
    Marzetti, A.
    Giovinazzo, G.
    Mancini, G.
    Marchetti, P.
    Ronzino, G.
    [J]. ORAL ONCOLOGY, 2009, : 195 - 195
  • [38] Clinical outcome of advanced and metastatic renal cell carcinoma treated with targeted therapy: is there a difference between young and old patients?
    Zhang, Guiming
    Zhu, Yao
    Dong, Dahai
    Gu, Weijie
    Zhang, Hailiang
    Sun, Lijiang
    Ye, Dingwei
    [J]. ONCOTARGETS AND THERAPY, 2014, 7 : 2043 - 2052
  • [39] Clinical outcomes of locally advanced esophageal neuroendocrine carcinoma treated with chemoradiotherapy
    Honma, Yoshitaka
    Nagashima, Kengo
    Hirano, Hidekazu
    Shoji, Hirokazu
    Iwasa, Satoru
    Takashima, Atsuo
    Okita, Natsuko
    Kato, Ken
    Boku, Narikazu
    Murakami, Naoya
    Inaba, Kouji
    Ito, Yoshinori
    Itami, Jun
    Kanamori, Jun
    Oguma, Junya
    Daiko, Hiroyuki
    [J]. CANCER MEDICINE, 2020, 9 (02): : 595 - 604
  • [40] Multimodality therapy for locally advanced thymomas: State of the art or investigational therapy?
    Huang, James
    Riely, Gregory J.
    Rosenzweig, Kenneth E.
    Rusch, Valerie W.
    [J]. ANNALS OF THORACIC SURGERY, 2008, 85 (02): : 365 - 367